---
category: news
title: "Ei­sai’s can­cer drug Halaven at the cen­ter of $2B pact with Bliss­Bio, like its Bris­tol My­ers ADC deal"
excerpt: "Eisai plans to pay up to $2 billion to develop an antibody-drug conjugate with Chinese biotech Bliss Biopharmaceutical, and the Japanese biopharma could gain ex-Greater China rights to the ADC, which includes its cancer med Halaven."
publishedDateTime: 2023-05-08T14:58:00Z
originalUrl: "https://endpts.com/eisais-cancer-drug-halaven-at-the-center-of-2b-pact-with-blissbio-like-its-bristol-myers-adc-deal/"
webUrl: "https://endpts.com/eisais-cancer-drug-halaven-at-the-center-of-2b-pact-with-blissbio-like-its-bristol-myers-adc-deal/"
type: article
quality: 1
heat: 1
published: false

provider:
  name: ENDPOINTS NEWS
  domain: endpts.com

topics:
  - AI in Healthcare
  - AI

secured: "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;lnyvP7JjXnnKoxcpcc8h7A=="
---

